All News

Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.

In patients with ES-ECLC treated with chemotherapy and immunotherapy, stereotactic body radiation therapy did not significantly improve overall survival.

Results from the phase 3 DESTINY-Breast09 trial will support the FDA’s decision on whether to approve T-DXd plus pertuzumab in frontline metastatic breast cancer.

CAR T-cell therapies or other agents that affect the immune system in the long term may be important to keep in mind for the management of SCLC.

Marc S. Raab, MD, PhD, details how agents such as carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.

Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.

Patients with mantle cell lymphoma who are older and have less fitness may be eligible for regimens that include bendamustine/rituximab.

IMNN-001 exhibits prolonged favorable safety among patients with advanced newly diagnosed ovarian cancer.

Employing patient-reported outcomes may help include those with small cell lung cancer in the shared decision-making process.

Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.

Data from the phase 3 evERA trial show a trend toward improved overall survival with giredestrant plus everolimus in this breast cancer population.

The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.

At 30 months, mitazalimab plus mFOLFIRINOX achieved an OS rate of 21% in patients with previously untreated metastatic PDAC.

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.

In the SWOG S2409 PRISM trial, over 800 patients with small cell lung cancer will receive different treatment regimens based on their disease subtype.

No TRAEs leading to dose discontinuation, DLTs, or belantamab-related corneal events above grade 1 occurred with belantamab in multiple myeloma.

Updated findings from AURIGA support the value of adding subcutaneous daratumumab to lenalidomide maintenance in MRD-positive NDMM after transplant.

Gary Steinberg, MD, compared the AE profile of the gemcitabine intravesical system for BCG-unresponsive NMIBC with other intravesical therapies.

Phase 1b/2 BGB-11417-105 trial data showed low rates of high-grade infection and hematologic toxicity with sonrotoclax-based therapy in multiple myeloma.

Patients with PDAC and non-GOF mutations had less favorable OS and DFS outcomes in various instances compared with those who had wild-type genes or GOF mutations.

Belantamab mafodotin plus lenalidomide and dexamethasone yielded a stringent CR of 42.9% in patients with newly diagnosed multiple myeloma.

Daratumumab, lenalidomide, ixazomib, and dexamethasone yielded PFS/OS outcomes in transplant-ineligible, newly diagnosed myeloma.

The agency has recommended approval for subcutaneous pembrolizumab in all previous solid tumor indications, and for pembrolizumab in recurrent HNSCC.

In patients with LS-SCLC who were ineligible for a prophylactic cranial irradiation, toripalimab appeared to decrease the progression of brain metastases.

Data from the TANDEMM trial show enduring responses with concurrent anti-GPRC5D and anti-BCMA therapy in relapsed/refractory multiple myeloma.

Data from the phase 3 3475A-D77 trial support the FDA approval of subcutaneous pembrolizumab across different pediatric and adult solid tumor indications.

Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.

The long-term safety profile of equecabtagene autoleucel was manageable, with no new safety signals identified in those with multiple myeloma.

As a 1-time dose, arlo-cel yielded promising efficacy and safety for patients with previously treated relapsed/refractory multiple myeloma.